Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Bigner, MD, PhD Faillot and coworkers [21] also performed a phase I study to evaluate whether a single IV injection could deliver an adequate amount of anti-EGFR monoclonal antibody (MAb 425 ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), reports an update on the Phase III SKYSCRAPER-01 study, ...

The quality of life for patients with metastatic colorectal cancer is improving and extending. The phase 2 academic study, ...

Genentech/Roche), a monoclonal antibody (mAb) specific for HER2, in patients with breast cancer. Another emerging class of companion diagnostics detect mutations in the gene encoding KRAS to guide ...

The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.

After hours: November 22 at 6:40 PM EST ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

Kelun-Biotech’s TROP2 ADC sacituzumab tirumotecan receives China NMPA marketing approval for 2L+ advanced or metastatic TNBC: Chengdu Thursday, November 28, 2024, 10:00 Hrs [IST ...